Constellation’s Oncology Pipeline


Constellation is pursuing discovery programs against multiple targets in the reader, writer, and eraser classes of epigenetic proteins. Constellation has developed proprietary tools and assays to biologically validate the function of the members of these target classes. In parallel, Constellation is employing its integrated expertise in biochemistry, biophysics, medicinal chemistry, pharmacology and translational medicine to advance these discovery programs to the clinic. In 2012, Constellation joined Genentech in an exclusive strategic alliance to broadly explore and validate additional targets in epigenetics and to discover and develop novel small molecule therapeutics against these important targets. Several programs resulted from this collaboration, which are currently being advanced.